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Part I, Physiology, begins with a history of platelets, from their recognition by Donné in 1842. Platelet plugs were recognized by Bizzozero in 1882, and that same year Hayem recognized that thrombocytopenia would lead to impaired hemostasis. Interest in platelets waned until the late 1940s. The initial chapter by Mustard, Kinlough-Rathbone and Packham reviews platelet research from the time of Donné and includes highlights over the 160 years since platelets were identified. The chapter includes a table that lists the highlights in platelet research over the years. This section also includes chapters on platelet production, morphology, and heterogeneity, and on the cytoskeleton and organelles. There is a chapter on platelet membrane proteins as adhesion receptors, and several chapters on specific platelet membrane receptors. There are chapters on platelet signaling, focusing on Ca ++ , protein kinase C, tyrosine kinase, cyclic nucleotides, and phospholipases. There are also chapters on various aspects of platelet function -shape change, aggregation, the release reaction, thromboxane generation and procoagulant activity. The section ends with chapters on platelets and chemotaxis, platelet-leukocytes interactions, and vascular interactions with platelets.
Part II, Methodology, is brief and includes chapters on in vitro assays of platelet function, monitoring antiplatelet therapy, flow cytometric analysis of platelet function, and animal models of platelet-dependent thrombosis.
Part III, Pathology, is divided into three sections -Hemostasis, Thrombosis, and Non-hemostatic disorders. Hemostasis consists of chapters on thrombocytopenia of various causes, thrombocytosis and thrombocythemia, and congenital and acquired disorders of platelet function, as well as a chapter on platelet storage and transfusion. Thrombosis includes chapters on platelets in atherosclerosis, arterial thrombosis and venous thromboembolism, as well as gene regulation of platelet function. The section on platelets and non-hemostatic disorders considers platelets and infectious agents, tumours, renal disease, allergic and other inflammatory diseases, and psychiatric and neurologic disorders. There is also a chapter on platelets and the pre-implantation stage of embryo development.
Part IV, Pharmacology, contains chapters on aspirin, ADPreceptor blockers, GPIIb-IIIa antagonists, and other antiplatelet agents. It also has a chapter on pharmacogenetics and one on cardiovascular gene therapy, as well as a chapter on pharmacological modulation of inflammatory actions of platelets.
Part V, Therapy, is the final section, and it discusses trials to evaluate antiplatelet agents and the use of antiplatelet agents in cardiology, neurology and peripheral vascular disease. The volume concludes with an afterword by Gustav Born, which is a delightful review of his own work on platelet function, beginning in the mid-1950s, including his development of the optical aggregometer and his early work with adenine nucleotides in platelets.
Having surveyed the content of the volume, I'll turn now to reviewing a few chapters from the different sections. Because I spent several years in the 1970s working on platelet alpha granule release, I'll start with Chapter 7, Platelet organelles, by F Rendu and B Brohard-Bohn. This brief chapter describes platelet dense granules alpha granules and lysosomes. The dense tubular system is mentioned but not discussed (its structure is described in the chapter on morphology and ultrastructure). This chapter is generally a good review of what is known about the structure and function of the different platelet granules. There are, however, a few minor problems. In the discussion of Hermansky-Pudlak syndrome (HPS), with reference to dense granules, the authors mention tyrosinepositive oculocutaneous albinism rather than tyrosinase-positive. Also with regard to both HPS and the Chediak-Higashi syndrome (CHS, another disorder of pigmentation and granules), identification of mutated genes that lead to truncation or loss of the HPS or CHS protein is discussed, but there is no mention of whether functions have been identified for these proteins. In their discussion of platelet-specific alphagranule proteins, the authors describe platelet basic protein (PBP), connective tissue activating protein-III (CTAP-III), and neutrophil-activating protein-2 (NAP-2) as precursors of ␤-thromboglobulin (␤-TG) and platelet factor 4 (PF4). This is not, however, an accurate description of the relationship of these proteins. PBP is the largest in a family of proteins (94 amino acids (aa)). CTAP-III is an 85 aa peptide produced by N-terminal proteolysis of PBP and ␤-TG is an 81 amino acid protein resulting from cleavage of a four aa N-terminal peptide from CTAP-III. It has also been referred to as low-affinity PF4. Nterminal proteolysis of ␤-TG yields NAP-2 (residues 25-94 of PBP). PF4 is a distinct protein from members of the ␤-TG family. Additionally, in their discussion of Quebec platelet disorder, the authors say that qualitative defects in factor V, thrombospondin, von Willebrand factor, and fibrinogen were reported, but the paper cited describes partial degradation of these alpha-granule proteins. Also, the authors refer to the Gray syndrome rather than the gray platelet syndrome as this defect in targeting or storing proteins in alpha-granules is usually denoted. It is not clear, in this chapter, how the authors chose what to reference.
The second chapter that will be looked at is entitled 'In Vitro assays for evaluating platelet function' by Thiagarajan and Wu. The authors' emphasis is on tests that would allow assessment of hyperactivity, but they note that several of the tests they review are better at identifying defects in platelet function. The chapter begins with a very brief but clear review of platelet activation, adhesion and aggregation and secretion. The authors then review global tests of platelet function, including the bleeding time, the PFA-100 platelet analyzer, and the Clot Signature analyzer (for which clinical data were not available when the chapter was written). The descriptions of these two devices are very good. One point about the PFA-100 that is not mentioned is that the closure time is affected by the hematocrit. The discussion of abnormal results with the two PFA cartridges, collagen/ADP and collagen/epinephrine is somewhat confusing, even after reading the literature cited. One citation number is incorrect -none of the papers cited contain the information referred to. They next turn to a discussion of platelet aggregation tests -the standard optical detection system using platelet plasma-rich, then the whole blood aggregation system, a rapid platelet function assay based on the ability of activated platelets to bind fibrinogencoated beads and used to assess glycoprotein IIb/IIIa blockade, measurement of shear-induced platelet aggregation, and evaluation of platelet function under flow. The authors also review measurements of soluble activation markers, either in the plasma (PF4, ␤-TG, soluble P-selectin, and glycocalicin) or in the urine (␤-TG, thromboxane A 2 metabolites). Flow cytometry to detect circulating activated platelets, plateletderived microvesicles, and circulating platelet aggregates, all of which are associated with thrombosis, is then described briefly and there is a separate chapter devoted to flow cytometry as well. Finally, there is a brief discussion of tests of platelet gene polymorphisms, since it is possible that these may be
